Boston Scientific agreed to pay $150 million in cash plus up to $125 million if clinical and commercial milestones are met over four years for San Bruno, Calif.-based nVision Medical, a startup that offers a balloon for collecting cells from the fallopian tubes to help detect ovarian cancer. Boston Scientific is looking to conduct a 120-patient study for the device, which was already evaluated in three smaller studies.
Boston Scientific to acquire nVision Medical in $275M deal
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.